Eiger BioPharmaceuticals
Logotype for Eiger BioPharmaceuticals Inc

Eiger BioPharmaceuticals (EIGR) investor relations material

Eiger BioPharmaceuticals has been delisted
Eiger BioPharmaceuticals
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Eiger BioPharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases. The company’s therapeutic areas include infectious diseases, metabolic disorders, and genetic conditions. Eiger’s pipeline targets diseases with high unmet medical needs, and it works to bring new treatment options to patients who have limited alternatives. Its approach involves repurposing existing drugs and developing novel compounds to advance its treatment options through clinical trials and regulatory approvals. The company is headquartered in Palo Alto, California, and its shares are listed on the NASDAQ.